Literature DB >> 2968355

Effects of long-term diabetes and treatment with gangliosides on cardiac sympathetic innervation: a biochemical and functional study in mice.

F Tessari1, R A Travagli, R Zanoni, M Prosdocimi.   

Abstract

The effect of long-term diabetes on cardiac sympathetic innervation was investigated in genetically obese diabetic mice (db/db). Previous studies have shown the presence of a peripheral neuropathy starting a few months after birth, and we recently reported a significant reduction of myocardial norepinephrine (NE) levels in the hearts of diabetic mice at the age of 6 months. In the present study, histofluorescence analysis of comparable sections of cardiac tissue of both control and diabetic animals confirmed the picture of a sympathetic denervated heart in this experimental model. Furthermore, functional studies in isolated atria revealed a difference between the two groups of animals: in fact heart rate increases induced by transmural stimulation were significantly lower in diabetic mice. Since a bovine brain ganglioside mixture (Cronassial) has been extensively studied for its effect on peripheral diabetic neuropathy, a group of diabetic mice was treated throughout the sixth month with this drug (10 mg/kg/day i.p.). The ganglioside treated animals showed a marked recovery of atrial function and cardiac NE concentration. The above results clearly indicate sympathetic neural damage in db/db animals, likely related to an autonomic diabetic neuropathy and a possible protection by ganglioside of adrenergic nerves from this alteration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2968355     DOI: 10.1016/0891-6632(88)90026-8

Source DB:  PubMed          Journal:  J Diabet Complications        ISSN: 0891-6632


  6 in total

Review 1.  Diabetes and cardiovascular autonomic dysfunction: application of animal models.

Authors:  Katia De Angelis; Maria Claudia Irigoyen; Mariana Morris
Journal:  Auton Neurosci       Date:  2008-12-02       Impact factor: 3.145

Review 2.  Sphingolipids in obesity, type 2 diabetes, and metabolic disease.

Authors:  S B Russo; J S Ross; L A Cowart
Journal:  Handb Exp Pharmacol       Date:  2013

3.  Sphingolipid regulators of cellular dysfunction in Type 2 diabetes mellitus: a systems overview.

Authors:  Jessica S Ross; Sarah B Russo; Georgia C Chavis; Lauren A Cowart
Journal:  Clin Lipidol       Date:  2017-01-18

4.  Sensory and autonomic function and structure in footpads of a diabetic mouse model.

Authors:  Ying Liu; Blessan Sebastian; Ben Liu; Yiyue Zhang; John A Fissel; Baohan Pan; Michael Polydefkis; Mohamed H Farah
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

5.  Targeting mitochondrial dynamics by regulating Mfn2 for therapeutic intervention in diabetic cardiomyopathy.

Authors:  Lang Hu; Mingge Ding; Daishi Tang; Erhe Gao; Congye Li; Kaiyan Wang; Bingchao Qi; Jihuan Qiu; Huishou Zhao; Pan Chang; Feng Fu; Yan Li
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

6.  Cardiovascular changes in animal models of metabolic syndrome.

Authors:  Alexandre M Lehnen; Bruno Rodrigues; Maria Cláudia Irigoyen; Kátia De Angelis; Beatriz D'Agord Schaan
Journal:  J Diabetes Res       Date:  2013-03-14       Impact factor: 4.011

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.